EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
Management of biochemical recurrence after primary curative treatment for prostate cancer: a review
W Artibani, AB Porcaro, V De Marco, MA Cerruto… - Urologia …, 2018 - karger.com
How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR)
following primary curative treatment is a controversial issue. Importantly, this prostate …
following primary curative treatment is a controversial issue. Importantly, this prostate …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
P Cornford, J Bellmunt, M Bolla, E Briers, M De Santis… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)–European Society for Radiotherapy & Oncology (ESTRO)–International Society of …
(EAU)–European Society for Radiotherapy & Oncology (ESTRO)–International Society of …
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact …
Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after
radical prostatectomy are usually drawn in the absence of visibly recurrent disease. 68Ga …
radical prostatectomy are usually drawn in the absence of visibly recurrent disease. 68Ga …
Early salvage radiotherapy following radical prostatectomy
D Pfister, M Bolla, A Briganti, P Carroll, C Cozzarini… - European urology, 2014 - Elsevier
Context Depending on the pathologic tumour stage, up to 60% of prostate cancer patients
who undergo radical prostatectomy will develop biochemical relapse and require further …
who undergo radical prostatectomy will develop biochemical relapse and require further …
The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external …
Background The management of biochemical failure (BF) following external beam
radiotherapy (EBRT) for prostate cancer is controversial, due to both the heterogeneous …
radiotherapy (EBRT) for prostate cancer is controversial, due to both the heterogeneous …
Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
J Calais, J Czernin, WP Fendler, D Elashoff… - BMC cancer, 2019 - Springer
Background Salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence after
prostatectomy offers long-term biochemical control in about 50–60% of patients. SRT is …
prostatectomy offers long-term biochemical control in about 50–60% of patients. SRT is …
Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy
A Briganti, RJ Karnes, S Joniau, SA Boorjian… - European urology, 2014 - Elsevier
Background Early salvage radiotherapy (eSRT) represents the only curative option for
prostate cancer patients experiencing biochemical recurrence (BCR) for local recurrence …
prostate cancer patients experiencing biochemical recurrence (BCR) for local recurrence …
Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy
N Fossati, RJ Karnes, C Cozzarini, C Fiorino… - European urology, 2016 - Elsevier
Background Early salvage radiation therapy (eSRT) represents a treatment option for
patients who experience a prostate-specific antigen (PSA) rise after radical prostatectomy …
patients who experience a prostate-specific antigen (PSA) rise after radical prostatectomy …
Phytochemicals in prostate cancer: from bioactive molecules to upcoming therapeutic agents
Prostate cancer is a heterogeneous disease, the second deadliest malignancy in men and
the most commonly diagnosed cancer among men. Traditional plants have been applied to …
the most commonly diagnosed cancer among men. Traditional plants have been applied to …